DrugDashboards

Prograf

Tacrolimus · TACROLIMUS .5 mg/1 · Capsule, Gelatin Coated · Oral · Astellas Pharma US, Inc.

NDC 00469-0607-73 · 1 BOTTLE in 1 CARTON / 100 CAPSULE, GELATIN COATED in 1 BOTTLE · NDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The brand price has held steady around $3.66 per unit over the past year. Generic versions run $0.1518 per unit36× cheaper. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$3.66per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.2000per billing unit (1 MG)HCPCS J7507 · Jul 1, 2026
  • Part D plans paid (avg)$9.05per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$3.60per unitnegotiated price across 108 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$2.51per unitAstellas Pharma U.S., Inc. · Jan 1, 202668% of what pharmacies pay — a deeper discount than 76% of drugs with this benchmark
  • Medicaid generic ceiling (FUL)$0.2378per CAPweighted avg manufacturer price $0.1359 · Aug 1, 20266% of what pharmacies pay — a deeper discount than 95% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$3.60per unit
middle half $3.55$3.71 · 108 plans · Apr 1, 2026
Est. net of rebates
$2.16–$2.70
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
2%of plans cover it
tier 4 · prior auth 100% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.00$4.00Jun 2013Sep 2026$3.66
39 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$109.85
#90 count
$329.56

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicare Part B (ASP)

Payment limit per 1 MG
$0.200
HCPCS J7507 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$397,434
1,640 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 3 active manufacturers+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for tacrolimus (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 4 across plans
  • Costs ≥ $950/fill · avg $160.04 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA050708
TE code
AB
Approval date
Apr 8, 1994
Patents / exclusivity
0 patents, 3 exclusivities
TypeNumber / codeExpires
exclusivityODE-360Jul 16, 2028
exclusivityODE-360Jul 16, 2028
exclusivityODE-360Jul 16, 2028

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class I · OngoingDec 23, 2024
    Astellas Pharma US Inc.Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Manufacturers of Tacrolimus (Capsule, Gelatin Coated)

LabelerStrengthFirst seenLast seen
Astellas Pharma US, Inc.TACROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026
Astellas Pharma US, Inc.TACROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Astellas Pharma US, Inc.TACROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
Jubilant Cadista Pharmaceuticals Inc.TACROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026
Jubilant Cadista Pharmaceuticals Inc.TACROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Jubilant Cadista Pharmaceuticals Inc.TACROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
Panacea Biotec LimitedTACROLIMUS .5 mg/1Jul 15, 2026Sep 2, 2026
Panacea Biotec LimitedTACROLIMUS 5 mg/1Jul 15, 2026Sep 2, 2026
Panacea Biotec LimitedTACROLIMUS 1 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Prograf — NDC 00469-0607-73," retrieved September 3, 2026, https://drugdashboards.com/drug/00469060773.

Free to cite with attribution — see how the data is put together.